198 related articles for article (PubMed ID: 32571868)
1. Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie
Gamboa-Alonso CM; Figueroa-Parra G; Galarza-Delgado DA
Ann Rheum Dis; 2021 Jan; 80(1):e7. PubMed ID: 32571868
[No Abstract] [Full Text] [Related]
2. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
Xie W; Wang Y; Zhang Z
Ann Rheum Dis; 2021 Jan; 80(1):e6. PubMed ID: 32317316
[No Abstract] [Full Text] [Related]
3. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli
Romão VC; Cruz-Machado AR; Fonseca JE
Ann Rheum Dis; 2021 May; 80(5):e76. PubMed ID: 32561609
[No Abstract] [Full Text] [Related]
4. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
Favalli EG; De Lucia O; Biggioggero M; Del Papa N; Caporali R
Ann Rheum Dis; 2021 May; 80(5):e75. PubMed ID: 32561608
[No Abstract] [Full Text] [Related]
5. Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis.
Spinelli FR; Ceccarelli F; Di Franco M; Conti F
Ann Rheum Dis; 2021 Jan; 80(1):e9. PubMed ID: 32366521
[No Abstract] [Full Text] [Related]
6. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
Monti S; Montecucco C
Ann Rheum Dis; 2020 Jun; 79(6):e62. PubMed ID: 32327429
[No Abstract] [Full Text] [Related]
7. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
Pileggi GS; Ferreira GA; Reis APMG; Reis-Neto ET; Abreu MM; Albuquerque CP; Araújo NC; Bacchiega AB; Bianchi DV; Bica B; Bonfa ED; Borba EF; Brito DCSE; Duarte ÂLBP; Santo RCE; Fernandes PR; Guimarães MP; Gomes KWP; Kakehasi AM; Klumb EM; Lanna CCD; Marques CDL; Monticielo OA; Mota LMH; Munhoz GA; Paiva ES; Pereira HLA; Provenza JR; Ribeiro SLE; Junior LFR; Sampaio CSJC; Sampaio VS; Sato EI; Skare T; de Souza VA; Valim V; Lacerda MVG; Xavier RM; Pinheiro MM
Adv Rheumatol; 2021 Oct; 61(1):60. PubMed ID: 34620246
[TBL] [Abstract][Full Text] [Related]
8. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
Parperis K
Ann Rheum Dis; 2021 Jan; 80(1):e8. PubMed ID: 32321722
[No Abstract] [Full Text] [Related]
9. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
Moiseev S; Avdeev S; Brovko M; Novikov P; Fomin V
Ann Rheum Dis; 2021 Feb; 80(2):e19. PubMed ID: 32317315
[No Abstract] [Full Text] [Related]
10. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
[No Abstract] [Full Text] [Related]
11. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev
Spinelli FR; Ceccarelli F; Di Franco M; Conti F
Ann Rheum Dis; 2021 Feb; 80(2):e20. PubMed ID: 32345618
[No Abstract] [Full Text] [Related]
12. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
Erre GL; Ferraccioli ES; Piga M; Mangoni A; Passiu G; Gremese E; Ferraccioli G
Ann Rheum Dis; 2021 Mar; 80(3):e29. PubMed ID: 32424028
[No Abstract] [Full Text] [Related]
13. Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre
Graef ER; Liew JW; Kim AH; Sparks JA
Ann Rheum Dis; 2021 Mar; 80(3):e30. PubMed ID: 32424027
[No Abstract] [Full Text] [Related]
14. Antimalarials in rheumatic diseases.
Tett S; Cutler D; Day R
Baillieres Clin Rheumatol; 1990 Dec; 4(3):467-89. PubMed ID: 2093438
[TBL] [Abstract][Full Text] [Related]
15. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
[TBL] [Abstract][Full Text] [Related]
16. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
Bugatti S; De Stefano L; Bobbio-Pallavicini F; Montecucco C
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33087414
[No Abstract] [Full Text] [Related]
17. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
Hu C; Lu L; Wan JP; Wen C
Curr Med Chem; 2017; 24(20):2241-2249. PubMed ID: 28302011
[TBL] [Abstract][Full Text] [Related]
18. Response to: 'Implications of SARS-CoV-2 infection for patients with rheumatic disease' by Lin
Mathian A; Amoura Z
Ann Rheum Dis; 2022 Aug; 81(8):e153. PubMed ID: 32895236
[No Abstract] [Full Text] [Related]
19. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
20. Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli
Mathian A; Amoura Z
Ann Rheum Dis; 2021 Feb; 80(2):e26. PubMed ID: 32451345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
